Show simple item record

FieldValueLanguage
dc.contributor.authorSoon, Jason
dc.contributor.authorHoussami, Nehmat
dc.contributor.authorClemson, Michelle
dc.contributor.authorLockie, Darren
dc.contributor.authorFarber, Rachel
dc.contributor.authorBarratt, Alexandra
dc.contributor.authorElshaug, Adam
dc.contributor.authorHoward, Kirsten
dc.date.accessioned2023-03-26T22:44:12Z
dc.date.available2023-03-26T22:44:12Z
dc.date.issued2022en_AU
dc.identifier.urihttps://hdl.handle.net/2123/30283
dc.description.abstractObjectivesTo determine the total annual screening and further-investigation costs of investigating false-positive and true-positive mammograms in the Australian population breast-screening program.MethodsThis economic analysis used aggregate-level retrospective cohort data of women screened at a breast-screening clinic. Counts and frequencies of each diagnostic workup-sequence recorded were scaled up to national figures and costed by estimating per-patient costs of procedures using screening clinic cost data. Main outcomes and measures estimated were percentage share of total annual screening and further-investigation costs for the Australian population breast-screening program of investigating false-positive and true-positive mammograms. Secondary outcomes determined were average costs of investigating each false-positive and true-positive mammogram. Sensitivity analyses involved recalculating results excluding subgroups of patients below and above the screening age range of 50-74 years.ResultsOf 8235 patients, the median age was 60.35 years with interquartile range of 54.17-67.17 years. A total of 15.4% (ranging from 13.4 to 15.4% under different scenarios) of total annual screening and further-investigation costs were from investigating false-positive mammograms. This exceeded the share of costs from investigating true-positives (13%).ConclusionsWe have developed a transparent and non-onerous approach for estimating the costs of false-positive and true-positive mammograms associated with the national breast-screening program. While determining an optimal balance between false-positives and true-positive rates must rely primarily on health outcomes, costs are an important consideration. We recommend that future research adopts and refines similar approaches to facilitate better monitoring of these costs, benchmark against estimates from other screening programs, and support optimal policy development.en_AU
dc.language.isoenen_AU
dc.publisherCSIRO Publishingen_AU
dc.relation.ispartofAustralian Health Reviewen_AU
dc.rightsCreative Commons Attribution 4.0en_AU
dc.titleThe financial implications of investigating false-positive and true-positive mammograms in a national breast cancer screening programen_AU
dc.typeArticleen_AU
dc.identifier.doi10.1071/AH22120
dc.type.pubtypeAuthor accepted manuscripten_AU
usyd.facultySeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Healthen_AU
workflow.metadata.onlyNoen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.